Contineum Therapeutics, Inc. financial data

Symbol
CTNM on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 30 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2339% % -27%
Debt-to-equity 7% % -12%
Return On Equity -32% % 35%
Return On Assets -30% % -48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23,099,173 shares
Weighted Average Number of Shares Outstanding, Basic 28,115,548 shares 9.3%
Weighted Average Number of Shares Outstanding, Diluted 19,352,859 shares 470%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $51,782,000 USD 55%
General and Administrative Expense $16,208,000 USD 60%
Operating Income (Loss) $67,990,000 USD -56%
Nonoperating Income (Expense) $8,873,000 USD 12%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $42,258,000 USD -282%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $59,387,000 USD -67%
Earnings Per Share, Basic 0 USD/shares -12%
Earnings Per Share, Diluted -0.4 USD/shares 85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $42,633,000 USD 4.3%
Marketable Securities, Current $139,774,000 USD -19%
Cash, Cash Equivalents, and Short-term Investments $182,400,000 USD -15%
Assets, Current $184,927,000 USD -14%
Property, Plant and Equipment, Net $880,000 USD -0.9%
Operating Lease, Right-of-Use Asset $4,774,000 USD
Other Assets, Noncurrent $266,000 USD 8767%
Assets $190,847,000 USD -12%
Accounts Payable, Current $786,000 USD -44%
Employee-related Liabilities, Current $2,814,000 USD 29%
Accrued Liabilities, Current $4,098,000 USD 7.9%
Liabilities, Current $6,361,000 USD 9.6%
Operating Lease, Liability, Noncurrent $4,016,000 USD
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $10,377,000 USD 79%
Accumulated Other Comprehensive Income (Loss), Net of Tax $265,000 USD -53%
Retained Earnings (Accumulated Deficit) $162,224,000 USD -58%
Stockholders' Equity Attributable to Parent $180,470,000 USD -14%
Liabilities and Equity $190,847,000 USD -12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,412,000 USD -81%
Net Cash Provided by (Used in) Financing Activities $24,000 USD
Net Cash Provided by (Used in) Investing Activities $14,915,000 USD 71%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $527,000 USD -29%
Deferred Tax Assets, Valuation Allowance $35,548,000 USD 40%
Deferred Tax Assets, Gross $36,838,000 USD 44%
Operating Lease, Liability $5,493,000 USD -1.9%
Payments to Acquire Property, Plant, and Equipment $47,000 USD -68%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $59,683,000 USD -71%
Property, Plant and Equipment, Gross $2,706,000 USD 26%
Operating Lease, Liability, Current $1,477,000 USD 142%
Deferred Tax Assets, Operating Loss Carryforwards $14,478,000 USD 16%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $3,094,000 USD 20%
Operating Lease, Payments $378,000 USD
Additional Paid in Capital $342,400,000 USD 9.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $78,000 USD 28%
Deferred Tax Assets, Net of Valuation Allowance $1,290,000 USD 412%
Share-based Payment Arrangement, Expense $2,569,000 USD 12%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%